Skip to main content

Table 5 Prediction for reimbursement cost using medical records and claims data-based comorbidity index score

From: A comparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: a population-based investigation

  

Exp[coefficient] based on medical records

(95% Confidence interval)

Exp[coefficient] based on claims data

(95% Confidence interval)

Age[years]

≤ 49

1

 

1

 
 

50-59

1

(0.842-1.187)

1.02

(0.859-1.213)

 

60-69

0.92

(0.787-1.093)

0.96

(0.813-1.131)

 

≥ 70

0.87

(0.727-1.063)

0.91

(0.751-1.106)

Gender

male

1

 

1

 
 

female

0.96

(0.852-1.104)

0.97

(0.849-1.102)

Histologic subtype

squamous cell carcinoma

1

 

1

 
 

adenocarcinoma

0.98

(0.872-1.110)

0.97

(0.863-1.100)

 

bronchoalveolar carcinoma

0.69

(0.535-0.893)

0.69

(0.530-0.889)

 

large cell carcinoma

1.05

(0.540-2.058)

1

(0.508-1.964)

 

small cell carcinoma

0.38

(0.219-0.663)

0.39

(0.226-0.688)

 

other

0.84

(0.521-1.362)

0.84

(0.517-1.354)

Surgical treatment type

wedge resection

1

 

1

 
 

lobectomy

0.96

(0.721-1.296)

0.93

(0.697-1.253)

 

pneumonectomy

1.02

(0.733-1.438)

1.01

(0.720-1.417)

 

others

0.78

(0.425-1.451)

0.75

(0.402-1.386)

Pathologic stage

I

1

 

1

 
 

II

1.05

(0.923-1.206)

1.04

(0.908-1.188)

 

III

1.17*

(1.044-1.328)

1.15*

(1.020-1.295)

CCI score

0

1

 

1

 
 

1

1.11

(0.986-1.256)

0.98

(0.870-1.104)

 

2+

1.15

(0.972-1.374)

0.97

(0.859-1.094)

  1. *p < 0.05 according to multiple linear regression analysis using log-transformed reimbursement cost